Nanexa initiates complementary preclinical studies

Nanexa AB today announces that the company has initiated complementary preclinical studies to investigate what caused the moderate skin reactions that occurred in the company's phase I study with NEX-18, a depot formulation of 5-azacitidine.

As communicated previously, the inclusion of patients in the NEX-18 study has been paused due to moderate skin reactions at the injection site, and an investigation has been initiated to clarify the cause. The investigation is carried out in collaboration with the clinics in the study and is expected to be concluded during the fourth quarter 2021.

To make sure that the NEX-18 project proceeds in the most optimal way, Nanexa has initiated complementary preclinical studies in pigs that are expected to be concluded in the first quarter 2022.

"We are doing these complementary preclinical studies in pigs in order to get a clear understanding of what caused the skin reactions and how we could minimize local skin reactions in connection with NEX-18 administration," said David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa devlops its own products and has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nanexa initiates complementary preclinical studies